CNS vs GROW

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

CNS

59.9
AI Score
VS
GROW Wins

GROW

60.5
AI Score

Investment Advisor Scores

CNS

60score
Recommendation
HOLD

GROW

61score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CNS GROW Winner
Revenue 94.41M 15.24M CNS
Net Income 29.96M 41,000 CNS
Net Margin 31.7% 0.3% CNS
Operating Income 36.29M 332,635 CNS
ROE 9.9% 0.1% CNS
ROA 6.7% 0.1% CNS
Total Assets 450.12M 40.43M CNS
Cash 193.73M 19.14M CNS
Free Cash Flow 4.31M 1.14M CNS

Relative Price Performance (Last 90 Days)

CNS 1M: -5.6% · 3M: -6.9% GROW 1M: -14.6% · 3M: -8.9%

Current Technical Phase

CNS

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.8%), weak momentum, RSI 36

RSI (14): 36.2 · Price: $73.12

GROW

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.8%), weak momentum, RSI 37

RSI (14): 37.2 · Price: $2.87

Fundamentals Snapshot

Metric CNS GROW
Market Cap — —
Forward P/E 18.4 28.8
Trailing P/E 22.4 12.0
Revenue (TTM) — —
Revenue Growth 0.1% 0.4%
Gross Margin 0.5% 0.5%
Operating Margin 0.3% 0.0%
EPS 3.26 0.24
Dividend Yield 0.04% 0.03%

Frequently Asked Questions

Based on our detailed analysis, GROW is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.